Trials / Terminated
TerminatedNCT00862121
A Study With Pentasa in Patients With Active Crohn's Disease
PENTASA in Active Crohn's Disease: A 10-week, Double-blind, Multi-centre Trial Comparing PENTASA Sachet 6 g/Day (Mesalazine, Mesalamine) With Placebo.
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose and a 4 g evening dose is efficacious in active mild to moderate CD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pentasa | 6 g/day orally, 2 g in the morning and 4 g in the evening |
| DRUG | Placebo | 6 g/day orally, 2 g in the morning and 4 g in the evening |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2009-03-16
- Last updated
- 2012-03-16
- Results posted
- 2012-03-12
Locations
15 sites across 7 countries: United States, Belgium, Denmark, France, Germany, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00862121. Inclusion in this directory is not an endorsement.